Showing 4391-4400 of 8735 results for "".
- FDA Approves Two New indications for Cosentyxhttps://practicaldermatology.com/news/fda-approves-tow-new-indications-for-cosentyx/2458745/The FDA has approved Cosentyx® (secukinumab, Novartis) for two new indications - the treatment of adult patients with active ankylosing spondylitis (AS) and active psoriatic arthritis (PsA). AS and PsA are both life-long, painful and debilitating inflammatory diseases tha
- Psoria-Shield, Inc. Names Dr. Steven Feldman as Scientific Advisorhttps://practicaldermatology.com/news/psoria-shield-inc-names-dr-steven-feldman-as-scientific-advisor/2458754/Psoria-Shield, Inc. Names Dr. Steven Feldman as Scientific Advisor Wellness Center USA, Inc.’s wholly owned subsidiary, Psoria-Shield, Inc. (PSI) named Steven Feldman, MD, PhD as Scientific Advisor. Dr. Feldman is a Professor of Dermatology, Professor of Pathology, and Professor of
- New Blood Test Gets Leg Up On Advanced Melanomahttps://practicaldermatology.com/news/new-blood-test-gets-leg-up-on-advanced-melanoma/2458756/A blood test that monitors blood levels of DNA fragments from dead cancer cells may be better at tracking progression of metastatic melanoma than the current standard blood test. The standard test measures blood levels of the enzyme lactate dehydrogenase (LDH), which tend t
- Allergan Expands Neurotoxin Pipeline with Anterios Acquisitionhttps://practicaldermatology.com/news/allergan-expands-neurotoxin-pipelinewith-anterios-acquisition/2458763/Allergan plc has acquired Anterios, Inc., a clinical stage biopharmaceutical company developing a next generation delivery system and botulinum toxin-based prescription products. Under the terms of the agreement, Allergan acquired Anterios for an upfront payment of $90 million and potential devel
- Vyome Biosciences Announces FDA Acceptance of Investigational New Drug Application for VB-1953 to Treat Acnehttps://practicaldermatology.com/news/vyome-biosciences-announces-fda-acceptance-of-investigational-new-drug-application-for-vb-1953-to-treat-acne/2458766/The FDA accepted Vyome Biosciences’ Investigational New Drug (IND) Application for the initiation of clinical studies for VB 1953, a topical therapeutic candidate for the treatment of moderate-to-severe acne. Vyome plans to start the Phase I clinical trials very soon. “Today m
- Anacor Submits NDA for Crisaborole Topical Ointment, 2% for the Treatment of Mild-to-Moderate Atopic Dermatitishttps://practicaldermatology.com/news/anacor-submits-nda-for-crisaborole-topical-ointment-2-for-the-treatment-of-mild-to-moderate-atopic-dermatitis/2458765/Anacor Pharmaceuticals, Inc. has submitted a New Drug Application (NDA) to the US FDA seeking approval of crisaborole topical ointment, 2%, a novel non-steroidal topical anti-inflammatory phosphodiesterase-4 (PDE-4) inhibitor in development for the potential treatment of mild-to-moderate atopic d
- Immune and BioNanoSim Enter Agreement to Develop Novel Topical Nano-Capsule Formulation of Cyclosporinehttps://practicaldermatology.com/news/immune-and-bionanosim-enter-agreement-to-develop-novel-topical-nano-capsule-forumlation-of-cyclosporine/2458768/Immune Pharmaceuticals Inc. entered into an exclusive worldwide licensing and development agreement with BioNanoSim Ltd. for a novel topical nano-capsule formulation of cyclosporine, also known as cyclosporine-A or CsA. Monica Luchi, M.D., Chief Medical Officer of Immune, commented: "
- MELA Sciences Changing Name to STRATA Skin Sciences to Reflect Broader Dermatology Commitmenthttps://practicaldermatology.com/news/mela-sciences-changing-name-to-strata-skin-sciences-to-reflect-broader-dermatology-commitment/2458771/MELA Sciences, Inc. will be changing its corporate name to STRATA Skin Sciences, Inc. effective Tuesday, January 5, 2016 and it will trade under the symbol “SSKN” on the Nasdaq Stock Market. Michael R. Stewart, President and Chief Executive Officer stated: “Our June 2015
- New Rosacea Research Findings Presented During SID Annual Meetinghttps://practicaldermatology.com/news/new-rosacea-research-findings-presented-during-sid-annual-meeting/2458777/Medical scientists reviewed research on the microbiome, genetics and pathophysiology of rosacea and presented results of new studies funded by the National Rosacea Society (NRS) during its research workshop at the Society for Investigative Dermatology annual meeting. “Research suppo
- AADA Supports New Bill to Protect Senior Access to Dermatologic Carehttps://practicaldermatology.com/news/aada-supports-new-bill-to-protect-senior-access-to-dermatologic-care/2458781/The American Academy of Dermatology Association (AADA) supports the Medicare Advantage Bill of Rights Act, introduced by Sen. Sherrod Brown (D-Oh.) and Rep. Rosa DeLauro (D-Conn.). If passed, the legislation would ensure that patients will have adequate physician networks in their Medicare Advant